Publication Date:
2011-04-09
Description:
〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Cooper, Matthew A -- Shlaes, David -- England -- Nature. 2011 Apr 7;472(7341):32. doi: 10.1038/472032a.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Institute for Molecular Bioscience, University of Queensland, Brisbane St Lucia, QLD 4072, Australia. m.cooper@imb.uq.edu.au〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21475175" target="_blank"〉PubMed〈/a〉
Keywords:
*Anti-Bacterial Agents/biosynthesis/economics
;
Clinical Trials, Phase III as Topic/economics
;
Drug Design
;
Drug Discovery/economics/legislation & jurisprudence/*methods/*trends
;
Drug Industry/economics/legislation & jurisprudence/*trends
;
*Drug Resistance, Bacterial
;
Federal Government
;
Humans
;
International Cooperation
;
Leadership
;
Models, Economic
;
United States
;
United States Food and Drug Administration/legislation & jurisprudence
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink